[heckel NEWS LETTER] 2019년 9월호

관리자 2019.10.01 조회 251

1) Save the date: Re-Bestrahlungsworkshop am Ordensklinikum Linz 14./15. May 2020

More information: http://www.ordensklinikum.at/re-bestrahlung2020 - Abstract Submission Deadline 16. March 2020.

There is an increasing interest in Re-Irradiation for local tumor control.
Because the combination with superficial hyperthermia allows for reduced re-irradiation doses - as shown by Notter M, Piazena H, Vaupel P 2017 - heckel will be a silver sponsor and will be present at the exhibition.


2) Whole-Body Hyperthermia at DGHT Congress 20./21. September 2019 in Berlin

▲Dr. Sebastian Zschaeck, from Charité University Berlin, Department of Radiooncology, reviewed the clinical data of fever-range WBH, emphasizing the need for more clinical studies, also planned at Charité University. 

▲Dr. Stefan Hiller and Brigitte Deckers, from Filderklinik near Stuttgart, gave an overview of the principles of integrative oncology in an anthroposophic hospital and reported their use of fever-range whole-body hyperthermia.
It is used in palliative, as well as in adjuvant settings, usually approximately 1 treatment per month. Main aims are the mitigation of side-effects of chemotherapy and the stimulation of anti-cancer immune surveillance.

▲Dr. Kay-U. Hanusch, from Emmenspital, in Switzerland reported a systematic review of 7 studies and 148 subjects on The impact of whole-body hyperthermia interventions on mood and depression, published OPEN ACCESS in the International Journal of Hyperthermia Volume 36, 2019 - Issue 1

3) Hyperthermia at Medizinische Woche Baden-Baden 30.10. - 03.11. 2019

Friday, 01.11.2019
09:00 - 12:30 Uhr - Kongresssaal I (1. floor)
Vortragstagung Hyperthermie - http://www.medwoche.de/5550.htm  GERMAN LANGUAGE
Sunday, 03.11.201909:00 - 12:45, Kongresssaal III (2.OG)

11:00 - 12:30 onkologische "fever-range" Ganzkörperhyperthermie  GERMAN LANGUAGE

- 11:00 - 11:30 Kleef/Wien: Coley remembered – back to the roots. Fever therapy of cancer in the light of modern immunology
- 11:30 - 12:00 Hübenthal/Zürich: Ganzkörper-Hyperthermie in der onkologischen Tagesklinik
- 12:00 - 12.30 Santos Martin/Grenollers (Spanien): Immunologische Daten zur Beurteilung der Effektivität der Ganzkörperhyperthermie. Kasuistiken

Visit the heckel booth UG-23!


4) Presentation of Complete Response of Stage IV Pancreatic Cancer at CICON 2019 Immunotherapy Conference in Paris by Kleef R et al.

At the conference, CICON 2019 - TRANSLATING SCIENCE INTO SURVIVAL from September 25.-28., 2019 in Paris, Ralf Kleef et al. from Vienna presented a case report on "Complete response of stage IV pancreatic cancer combining dose adapted checkpoint inhibitors with interleukin-2 (IL-2) and fever range hyperthermia". 
This presentation follows several presentations at international academic conferences, listed in the Selected publications and Running clinical trials auf www.heckel-hyperthermia.com - look at Oncology / 6. Congress abstracts.

Systematic pre-clinical research has revealed the powerful effects of fever-range hyperthermia on anti-cancer immune functions - reviewed in Repasky EA, Evans SS, Dewhirst M (2013): Temperature Matters! And Why it Should Matter to Tumor Immunologists.

It is evident that fever-range hyperthermia cannot act as a monotherapy in cancer therapy, but can probably significantly increase the effects of other immunotherapies. The new approach of a multi-modular therapy, including dose-reduced checkpoint inhibitors and fever-range whole-body hyperthermia, might be one example where one of the most ancient immune stimulating therapies could find its place in modern cancer therapy.


본 게시물은 독일 heckel gmbH.에서 발행한 뉴스레터의 내용입니다.